Originariamente Scritto da
flag
io mi sono guardato i primi studi da te linkati (alcuni già discussi qui)
The 3-dose VE was 94.0% (92.3%-95.4%) and 67.7% (65.5%-69.7%) against delta and omicron infection, respectively, and 21.7% (0.0%-45.0%) against omicron infection in immunocompromised individuals.
The 3-dose VE against hospitalization with delta or with omicron was above 99%.
While variants and waning efficacy are relevant,
SARS-CoV-2 vaccines reduce the risk of infection, transmission, and severe illness/hospitalization in adults. Thus, higher vaccination levels are beneficial by reducing healthcare system pressures and societal fear. However, the benefits of excluding unvaccinated people are unknown.
Vaccines are beneficial, but the high NNEs suggest that excluding unvaccinated people has negligible benefits for reducing transmissions in many jurisdictions across the globe.
This is because unvaccinated people are likely not at significant risk – in absolute terms – of transmitting SARS-CoV-2 to others in most types of settings since current baseline transmission risks are negligible. Consideration of the harms of exclusion is urgently needed, including staffing shortages from losing unvaccinated healthcare workers, unemployment/unemployability, financial hardship for unvaccinated people, and the creation of a class of citizens who are not allowed to fully participate in many areas of society. (
mi piacerebbe vedere il modello di questo studio)
s
However,
although the vaccination strongly contributed to limit the number of infected people among the vaccinated individuals, some vaccinated person can be infected, often asymptomatically.31
Furthermore, the role of emerging new viral variants, as the Delta and the Omicron variants, continuously represents a
challenge for the scientific community to block the circulation of the virus, which represents a considerable risk for global health.32
Indeed, even though
the efficacy of COVID-19 vaccines has been demonstrated to be maintained against at least for the Delta variant,33
as also confirmed by our findings, it is very likely that an incomplete cycle of vaccination or the persistent circulation of the virus can lead to a decrease in efficacy or to the onset of new variants able to escape the immune response elicited by the vaccines.34
Within this frame, reconsidering the strategy of vaccination to prevent not only the severe disease but the viral infection (i.e., the so-called ‘sterilizing immunity’), should represent the goal for the generation of second line COVID-19 vaccines, aimed to reinforce the mucosal immune response.35
We found B.1.1.529 to be markedly resistant to neutralization by serum not only from convalescent patients, but also from individuals vaccinated with one of the four widely used COVID-19 vaccines. Even serum from persons vaccinated and boosted with mRNA-based vaccines exhibited substantially diminished neutralizing activity against B.1.1.529.
The Omicron variant presents a serious threat to many existing COVID-19 vaccines and therapies, compelling the development of new interventions that anticipate the evolutionary trajectory of SARS-CoV-2.
Our study provides evidence of protection against infection with the Omicron variant after completion of a primary vaccination series with the BNT162b2 or mRNA-1273 vaccines; in particular, we found a VE against the Omicron variant of 55.2% (95% confidence interval (CI): 23.5 to 73.7%)
and 36.7% (95% CI: -69.9 to 76.4%) for the BNT162b2 and mRNA-1273 vaccines, respectively,
in the first month after primary vaccination. However, the VE is significantly lower than that against Delta infection and declines rapidly over just a few months. The VE is re-established upon revaccination with the BNT162b2 vaccine (54.6%, 95% CI: 30.4 to 70.4%).
In this retrospective large cohort study, performed in
individuals who received two doses of the BNT162b2 mRNA vaccine, protection seemed to decrease over time, and the risk of breakthrough infection by SARS-CoV-2 increased progressively compared with the protection provided during the initial 90 days. Interpretation of the findings of
the study is limited by the observational design, but the results suggest that consideration of a third vaccine dose might be warranted.
sull'articolo (unico autore) del lancet-regional, direi che è il giusto prosieguo di quest'altro articolo (non lo è , è solo una lettera all'editore, ma qui è stato presentato tempo fa come uno studio...per dire il livello di approssimazione)
https://www.thelancet.com/journals/l...inkback-header
comunque anche questo è interessante
https://jamanetwork.com/journals/jam...rticle/2788485
Among individuals seeking testing for COVID-like illness in the
US in December 2021, receipt of 3 doses of mRNA COVID-19
vaccine (compared with unvaccinated and with receipt of 2
doses) was less likely among cases with symptomatic SARS-
CoV-2 infection compared with test-negative controls. These
findings suggest that receipt of 3 doses of mRNA vaccine, rela-
tive to being unvaccinated and to receipt of 2 doses, was as-
sociated with protection against both the Omicron and Delta
variants, although the higher odds ratios for Omicron suggest
come sappiamo, il vaccino funziona meno con omicron, ma questo non significa che non funzioni per nulla
ripeto poi che su interventi non farmacologici ma sociali, che in quasi tutti i lavori salvo quello di , come si chiamava....kampf ? sono richiamati , possiamo essere più o meno d'accordo, oltretutto su 3 direttrici diverse, che andrebbero separate per capirci qualcosa, quella clinica, quella economica e quella etica....
basta postare lavori a raffica, che poi me li leggo tutti, grazie
less protection for Omicron than for Delta.
credo un po' di più, e sono stati sospesi, come succede, per motivi etici, quando il risultato del farmaco vs placebo è evidentemente superiore
gli studi sono stati fatti su wuhan, però
io sono affetto da ideologia e preconcezione?!?, ma alle XXX mi sono fermato perchè mi girava la testa
comunque le cause le hanno capite, e noncielodicono
